IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Examiner: Owens, Amelia A.

Frederic Galli

Filed:

Art Unit

1625

Serial No.: 10/500,015

June 23, 2004

Title: Derivatives of 5-(Pyridin-3-yl)-1-

azabicyclo[3.2.1]octane, the Preparation Thereof and the Application of Same in

Therapeutics

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Supplemental Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Supplemental Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

(a) This Supplemental Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

 \boxtimes This Supplemental Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first. (1) The undersigned attorney certifies that each item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement; The undersigned attorney certifies that no item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or \square (3) This Supplemental Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

Respectfully submitted,

October 30, 2006

Balaram Gupta, Reg. No. 40,009 Attorney/Agent for Applicant

sanofi-aventis Inc. LLC
U.S. Patent Operations
Route #202-206/ P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3364
Telefax (908) 231-2626

sanofi-aventis Docket No. SSL0046 US PCT

Please type a plus sign (+) inside this box	\rightarrow	7

Substitute for form 1449A/PTO INFORMATION STATEMENT B'

1

Sheet

PTO/SB/08A (10-96) Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

e for form 1449A/PTO DRMATION DISCLOSURE			Complete if Known		
			Application Number	10/500,015	
			Filing Date	06-23-2004	
TEMENT E	3Y A	APPLICANT	First Named Inventor	GALLI, et. al.	
(use as many sheets as necessary)			Group Art Unit	1625	
			Examiner Name	OWENS, Amelia A.	
1	of	1	Attorney Docket Number	SSL0046 - US - PCT	

U.S. PATENT DOCUMENTS						
Examiner Cite initials' No.1	U.S. Pater	t Document	Name of Patentee or Applicant of Cited Document	Date of Publication of	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
						Cited Document MM-DD-YYYY
			-++			
			-++			
-			-++			

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.1	Foreign Patent Document Kind Code ⁵ Office ³ Number ⁴ (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6	
		wo	95/03306		PIOTROWSKI, et. al.	02-02-1995	rigures Appear	
								\vdash

Examiner	Date	
Signature	Considered	

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.